Large And Small-Scale Bioprocessing Market Global Trends And Revenue Growth Up To 2030

Large And Small-Scale Bioprocessing Industry

The global large and small-scale bioprocessing market was valued at USD 80.5 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 13.8% from 2025 to 2030. Bioprocess engineering has proven to be an effective approach for the development of biopharmaceuticals, providing both bio-manufacturers and contract manufacturing organizations (CMOs) with lucrative opportunities for growth. As a result, there is expected to be a surge in focused efforts to enhance the adoption of various bioprocess engineering solutions across the market.

Large-scale bioprocessing involves the production of biopharmaceuticals and other biological products on a vast scale, typically utilizing large bioreactors and extensive facilities. In contrast, small-scale bioprocessing focuses on producing smaller batches, often employing micro-bioreactors and flexible systems that allow for more precise control over production conditions. Both approaches are vital for catering to a range of market demands, from the mass production of vaccines to the creation of personalized medicines. The increasing demand for biopharmaceuticals, driven by their ability to offer targeted therapies for chronic diseases such as cancer and diabetes, is one of the key factors propelling this market. This rising demand fuels investments in advanced technologies such as incubation systems and filtration devices, which are essential for ensuring that bioprocessing systems can scale efficiently while adhering to regulatory standards.

As bioprocessing technologies continue to evolve, manufacturers are embracing innovative solutions designed to improve efficiency, reduce costs, and enhance product quality. Technological advancements, including the adoption of single-use technologies and automation, play a crucial role in driving the market's growth. These innovations enable more cost-effective production methods, better process control, and a reduction in contamination risks. Furthermore, the growing trend toward personalized medicine requires scalable bioprocessing solutions capable of adapting to smaller batch sizes without compromising on product quality. This demand for customization further positions the bioprocessing market for substantial growth in the coming years.

Another key driver of market expansion is the increasing investment in biotechnology research. Both government and private sectors are channeling significant funding into biotechnological innovations, fostering collaborations between academic institutions, research organizations, and industry leaders. For example, the UK Bioindustry Association (BIA) has projected that UK biotechnology grant funding will see an increase in 2025/2026. The Biotech and Medical sector is expected to receive over USD 160 million for R&D and more than USD 50 million for capital investments in equipment. Furthermore, innovation funding is set to experience a five-fold increase, potentially reaching over USD 1 billion, with a focus on under-funded regions and sectors undergoing digital transformation, such as healthcare.

Curious about the Large And Small-Scale Bioprocessing Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Key Large And Small-scale Bioprocessing Company Insights

The players in the market are undertaking strategic initiatives to retain their significant share as well as to enhance industrial share. Strategic initiatives undertaken by the companies include product line enhancement, regional expansion, distribution network reinforcement, collaborations, and merger & acquisition.

• Corning, Inc. operates in the bioprocessing segment by manufacturing a range of cell culture and bioprocess solutions. These include vessels, media, and surface treatments for scaling up both anchorage-dependent and suspension cells. Corning's products support efficient scale-up and production in bioprocessing, offering closed system solutions to reduce contamination risks.
• Sartorius AG manufactures products such as bioreactors, filtration systems, and automation technologies that support both large-scale commercial production and small-scale research and development. Sartorius's offerings are designed to enhance efficiency, reduce costs, and improve product quality across various bioprocessing workflows, from upstream to downstream operations.

Key Large And Small-scale Bioprocessing Companies:

The following are the leading companies in the large and small-scale bioprocessing market. These companies collectively hold the largest market share and dictate industry trends.

• Merck KGaA
• Thermo Fisher Scientific, Inc.
• GE healthcare
• Corning, Inc.
• Sartorius AG
• CESCO BIOENGINEERING CO., LTD
• Bio-Process Group
• Bioprocess Control AB
• Eppendorf AG
• Applikon Biotechnology
• Lonza
• PBS Biotech, Inc
• Finesse
• Meissner Filtration Products, Inc.
• CellGenix GmbH
• Boehringer Ingelheim
• Samsung BioLogics
• Patheon
• CMC Biologics
• Binex Co., Ltd
• Rentschler Biotechnology GmbH
• TOYOBA CO., LTD.
• Inno Biologics Sdn Bhd
• Hoffmann-La Roche Ltd

Recent Developments

• In February 2025, Thermo Fisher Scientific is set to acquire Solventum's Purification & Filtration business for USD 4.1 billion, a strategic move to bolster its bioproduction capabilities. This acquisition enhances Thermo Fisher's offerings in both Large and Small Scale Bioprocessing by adding Solventum's innovative filtration technologies, complementing their existing cell culture media and single-use technologies. The deal, expected to close by the end of 2025, will integrate Solventum's purification and filtration solutions into Thermo Fisher's Life Sciences Solutions segment, promising better service to customers in the rapidly growing bioprocessing market, from upstream to downstream workflows in both Large and Small Scale Bioprocessing.
• In January 2025, Sartorius and McMaster University in Canada launched a new bioprocessing automation lab, enhancing biomanufacturing research and training. Sartorius contributed advanced equipment to the state-of-the-art facility, designed to accelerate developments in bioprocess modeling and simulation. The lab is expected to support training for students and industry partners, focusing on innovative solutions for both Large and Small Scale Bioprocessing. Funded in part by the Biosciences Research Infrastructure Fund, this initiative aims to address talent shortages and improve the efficiency of biotherapeutics manufacturing, ultimately expanding access to life-saving treatments through advancements in large and small scale bioprocessing industry.

Order a free sample PDF of the Large And Small-Scale Bioprocessing Market Intelligence Study, published by Grand View Research.